fewer thyroidectomies with new test?

Started by scienceguy19
Physicians and veterinarians: Turn your expertise into action! Explore CDC’s Epidemiology Elective Program and Epidemic Intelligence Service today.
This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.
Get help with your application

Use all the free resources available to you from SDN: articles, guides, expert advising, forums discussions, and school research.

Browse articles Compare schools My application plan Read Interview Feedback
Practice for interviews Ask an Advisor
Veracyte testing does seem promising. It has a high negative predictive value in AUS and suspicious for follicular neoplasm cases. I wouldn't worry about getting less thyroidectomies. As long as there are worried patients, and endocrine surgeons who encourage surgery on big lesions, there will be thyroids to examine.
 
Advertisement - Members don't see this ad
Yeah, this will reduce thyroidectomies by about 1%. They already follow a lot of these nodules, and patients want a lot of them out anyway.

What we really need is a study that shows that every circumscribed thyroid nodule is not going to kill the patient. FVPTC are more benign than non FV PTC.
 
Just curious- how many of you are asked to perform frozens on thyroids irrespective of prior FNA results?
 
i had one surgeon who always did but i have finally convinced him how silly it is to freeze a follicular nodule or a fna demonstrated pap ca
 
pathstudent said:
If anything hopefully it will reduce thyroid FNA specimens.

Don't like those at all.
Click to expand...


Since the FNA is what is used for the Veracyte test, i wouldn't count on less Thyroid FNA.

This test costs like 3500 dollars and I have a feeling it will prevent very few surgeries.

I been sending pulmonary specimens to Veracyte for years. They are working on some molecular tests for lung as well.
 
Veracyte's data from the Medicare 2012 website........Not bad considering how few specimens they had.


VERACYTE, INC.
Location
SOUTH SAN FRANCISCO, CALIF.
Specialty / Facility Type
Clinical Laboratory
Total Medicare payments in 2012
$3,820,909.43

ProcedureNumber performed Average payment per procedure Total payments for procedure
Clinical chemistry test 961 $3200.00 $3,075,200.00
Cytopath eval fna report 5673 $131.40 $745,432.20
Molecular rna stabilization 111 $7.45 $191.95
Molecule isolate nucleic 11 $5.32 $58.52
 
How are they getting paid $131.40 by medicare for a thyroid fna?? I'm getting $56 from medicare for FNA interpretations.
 
First off, I hate Dr Zaius from the first Planet of the Apes movie. He pissed me off big time because of his treatment of Cornelius, Zira and Taylor. God I thought Nova was hot. If I was Taylor I would have taken her to the forbidden zone and had some fun.

TC and PC combined would be my guess for what they are getting paid on 88173.

3200 dollars for 961 patients for that molecular test is what caught my eye. Over 3 million dollars......How many surgeries did they actually prevent is my question?

God I love that Medicare website. You can see who is swimming naked when the tide rolls out.
 
Last edited:
Agreed, Nova was ridiculously hot. Much moreso than Freida Pinto in the reboot.

TC+PC makes sense, thanks.

There was an abstract at the ATA a few years ago where Mayo reported their experience with veracyte. The rate of molecular "suspicious" dx was much higher than in the NEJM article and the PPV was far lower.

http://online.liebertpub.com/doi/pdfplus/10.1089/thy.2012.2209.abs

I don't understand how this test has gotten so much traction on the basis of 1 industry funded study.
 
In my territory it had initial traction but now it seems stuck in the mudd. Interest in the test has died off considerably. Someone was hitting the ENTs in my state heavy early on after FDA approval. Not sure if it was Veracyte or that Thyroid Cytopathology Partners lab. They sure have a lot of female pathologists at that Thyroid lab.

http://www.thyroidcytopath.com/about-us/

I have been working with Veracyte for years on some tests for interstitial lung disease. That is another area they are hoping to develop tests for.
 
Advertisement - Members don't see this ad
I just wonder what the state of thyroid malignancy will be in another 20 years. The survival rate for thyroid cancer now is almost better than any other type of cancer, with rare exception (anaplastic mostly, some medullary). A lot of things we call cancer don't really behave much like cancer. Where the molecular tests will have any utility will be in picking out the aggressive papillary cancers or follicular cancers or ones that could potentially go bad and cause significant morbidity. It's kind of like prostate cancer, it's just hard right now to pick out the bad ones. Maybe molecular will help, maybe it won't. But I have higher hopes for molecular in thyroid CA than I do in most other sites.
 
You must log in or register to reply here.